SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation A2063G

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There are 2 clinical trials

Clinical Trials


1 Studies on Macrolide-resistant Mycoplasma Pneumoniae in Taiwan- A Randomized Control Trial and MLVA Analysis

A randomized clinical trial comparing treatment effectiveness of azithromycin and doxycycline for pediatric Mycoplasma pneumonia.

NCT03530319 Pneumonia, Mycoplasma Drug: Doxycycline Drug: Azithromycin
MeSH:Mycoplasma Infections Pneumonia, Mycoplasma Pneumonia Pleuropneumonia
HPO:Pneumonia

In previous studies, the most common mutation point, A2063G, was detected from 23% of local strains in Taiwan. --- A2063G ---

Primary Outcomes

Description: The timing (days) when fever subsides after treatment

Measure: Defervescence

Time: Up to 10 days

Secondary Outcomes

Description: The length of hospitalization

Measure: Hospital stay

Time: Up to 2 weeks

2 Diagnosis and Treatment of Mycoplasma Pneumoniae and Vaccine Development

A randomized clinical trial comparing treatment effectiveness of azithromycin and doxycycline for pediatric Mycoplasma pneumonia.

NCT03911440 Atypical Pneumonia Drug: Doxycycline Drug: Azithromycin
MeSH:Mycoplasma Infections Pneumonia, Mycoplasma Pneumonia Pleuropneumonia
HPO:Pneumonia

In previous studies, the most common mutation point, A2063G, was detected from 23% of local strains in Taiwan. --- A2063G ---

Primary Outcomes

Description: The timing (days) when fever subsides after treatment

Measure: Defervescence

Time: Up to 10 days

Secondary Outcomes

Description: The length of hospitalization

Measure: Hospital stay

Time: Up to 2 weeks


HPO Nodes